The therapeutic uses of Диован (Valsartan) are relevant across several therapeutic domains. The medication is applied for various clinical indications, including the sustained control of elevated blood pressure (hypertension), the chronic management of heart failure, and supportive management following a recent heart attack in patients with impaired left ventricular function.

Диован is primarily used for conditions marked by increased physiological stress and symptoms related to systemic imbalance. This treatment contributes to foundational support by assisting with maintaining functional stability and managing the overall symptom load. The chronic management of heart failure, for instance, helps to address symptom clusters related to fluid overload and congestion, such as shortness of breath and swelling.

This relevance extends to specific groups, including pediatric patients managing hypertension and adults who require a different approach to treatment. The core benefit may assist with continuous cardiovascular support across these various patient needs.

Quick Fact: Relief for Cardiovascular Strain
This medication helps manage symptoms related to the long-term, continuous strain placed on the heart and arteries by high blood pressure and chronic cardiac conditions.

Eligibility Map: Who can and cannot use Диован (Valsartan) — Official Regulatory Information

This section outlines the population-based eligibility and non-eligibility rules for the medicine based solely on official government regulatory documents.

---

Eligibility Scope
Populations for whom use is allowed (as stated in label): Adults (18+) for all approved uses; Children and adolescents aged 6 to less than 18 years for the treatment of hypertension.
Populations for whom use is not recommended (if applicable): Children below 6 years of age; infants below 1 year; pediatric patients (under 18) for heart failure or post-myocardial infarction; patients with primary hyperaldosteronism.
Populations for whom use is contraindicated: Patients with a known hypersensitivity to valsartan; women in the second and third trimesters of pregnancy; patients with severe hepatic impairment, biliary cirrhosis, or cholestasis; and patients with diabetes mellitus or moderate-to-severe renal impairment receiving aliskiren.

---

Condition-Specific Eligibility Rules
Renal Impairment: Use requires caution in adult patients with severe impairment (creatinine clearance <10 mL/min). Use is not recommended in children with creatinine clearance <30 mL/min or those undergoing dialysis.
Hepatic Impairment: Use requires caution in patients with mild to moderate impairment without cholestasis.
Volume/Salt Depletion: This condition must be corrected prior to administration, or treatment must begin under close medical supervision.

---

Connection to the overall eligibility profile:

The official eligibility profile is defined by regulatory criteria that lists absolute contraindications related to late-stage pregnancy, severe liver disease, and specific drug-combination exclusions. Furthermore, the profile establishes age limits (e.g., 6 years for hypertension) and requires cautions for patients with impaired organ function or fluid depletion, establishing the mandatory constraints for use as determined by governmental authorities.

Interactions with other medicines and products

Official regulatory information for Диован (valsartan) identifies several classes of products that may interact with it, primarily by increasing the risk of high potassium levels (hyperkalemia) or by affecting kidney function.

Interacting Product Category	Key Constraint / Implication
Dual Blockade of the RAS (e.g., Aliskiren, ACE Inhibitors)	Concomitant use with aliskiren is contraindicated in patients with diabetes or moderate to severe renal impairment (GFR < 60 mL/min/1.73 m²). Dual blockade with other agents, such as ACE inhibitors, is generally not recommended due to increased risks of hyperkalemia, hypotension, and renal function changes.
Potassium-Sparing Diuretics/Supplements	The co-administration of potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase serum potassium levels. Close monitoring of blood potassium is necessary when these agents are used together.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Concomitant use, especially in elderly, volume-depleted, or kidney-impaired patients, may lead to a reduction of the blood pressure-lowering effect of Valsartan and may increase the risk of worsening renal function, including acute renal failure.
Lithium	Concurrent use of Valsartan with lithium has resulted in an increase in serum lithium concentrations and the potential for lithium toxicity. Monitoring of serum lithium levels is required if these medications are used together.

These official documented interaction statements guide co-administration and monitoring requirements. They mandate strict avoidance in specific patient groups for the dual blockade interaction and require careful clinical monitoring for effects on potassium and kidney function with other commonly used drug classes.

Диован, containing the active compound valsartan, functions as an Angiotensin II Receptor Blocker (ARB) by interfering with the renin-angiotensin-aldosterone system (RAAS).

Valsartan acts as a selective antagonist of the Angiotensin II type 1 ( AT1) receptor. This receptor is primarily located on the surface of vascular smooth muscle cells and in the adrenal gland. Valsartan exhibits high affinity for the AT1 receptor and occupies the receptor site, preventing the binding of the endogenous hormone, angiotensin II.

This interaction interrupts the AT1-mediated signaling cascade. The block directly results in the cessation of two key angiotensin II effects: the cellular signaling that induces vasoconstriction (narrowing of blood vessels) and the stimulation of the adrenal cortex that drives aldosterone secretion. The consequence is a reduction in systemic vascular resistance and a decrease in the body's retention of sodium and water, leading to a modulation of overall fluid balance and circulatory dynamics.

Valsartan (Диован) is administered exclusively through the oral route, available as a film-coated tablet in multiple strengths or as an oral suspension. The medicine may be taken with or without food, which provides flexibility for daily administration.

The required dosing frequency is dependent on the treated condition. For the sustained control of elevated blood pressure (hypertension), the medicine is typically taken once daily. However, for managing chronic heart failure or following a recent myocardial infarction (Post-MI), the dosing regimen requires administration twice daily in divided doses.

Therapy is initiated at a low starting dose and is subject to a structured step-wise titration to reach the target maintenance dose, a process that typically spans several weeks. The total daily maintenance dose range for adult hypertension is up to 320 mg. In the management of heart failure, the maximum recommended target dose is 320 mg per day, given in divided doses.

Specific administration rules apply to certain populations. For children (ages 6–16) with hypertension, the dosage is calculated based on body weight, starting at 1.3 mg/kg once daily, with the maximum dose not exceeding 160 mg per day. If a dose is missed, it should be taken as soon as it is remembered, unless it is close to the time for the next scheduled dose, in which case the missed dose should be skipped. Valsartan is intended for chronic, long-term use across its approved indications.

Research Evidence / Overview of studies for Диован (Valsartan)

---

Evidence for use in Controlling Elevated Blood Pressure (Hypertension)

Research exploring outcomes in patients with high blood pressure, or hypertension, primarily involved large-scale, long-term Randomized Controlled Trials (RCTs). These studies compared Valsartan to a neutral substance (placebo) or to other commonly studied medicines. The research specifically monitored changes in systolic and diastolic blood pressure (BP) over defined time intervals. Study populations included both adults with essential hypertension and dedicated studies in pediatric patients aged 6 to 16 years.

Studies reported that treatment was associated with measurable reductions in blood pressure. The long-term trials also monitored outcomes reflecting daily functioning and reported data collected on the rates of cardiovascular events, such as heart attack and stroke. Comparative research described similar patterns between the different single-agent treatment arms.

---

Evidence for use in Chronic Management of Heart Failure

For the chronic management of heart failure, the evidence relies on large, event-driven, placebo-controlled RCTs. Outcomes monitored included research into all-cause mortality and a combined endpoint that tracked deaths and hospitalizations related to phases of heightened symptom activity. The study populations focused on adults with symptomatic heart failure who had a documented reduced left ventricular ejection fraction (LVEF).

Studies reported data collected on rates of heart failure-related hospitalizations and on all-cause mortality in the treated groups when compared to those receiving a placebo. When researchers explored the use of Valsartan in combination with an existing ACE inhibitor, the reported outcomes described that the research did not indicate a difference in overall mortality rates in this specific setting.

---

What is Still Uncertain About Диован's Evidence

Findings describe group patterns, but research does not determine whether an individual will respond similarly. There are several areas where the evidence landscape suggests certainty remains low or where research is ongoing.

• Optimal Combination Therapy: Evidence is limited regarding the use of Valsartan in a triple-combination regimen (alongside an ACE inhibitor and a beta-blocker), as some research reported an increased incidence of certain findings in this combination without a survival benefit.
• Heart Failure Subtypes: Data for certain groups remain insufficient, particularly for the use of Valsartan alone in heart failure with a preserved ejection fraction (HFpEF).
• Long-Term Follow-up: Certain research limitations suggest that there is limited information for long-term outcomes that extend far beyond the typical four-to-six-year trial duration.

Key Studies & References

1. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
2. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Rationale and design

Common questions about Диован (FAQ)

Q: What is Диован used for?

Диован (valsartan) is generally indicated for managing high blood pressure (hypertension). It is also used to treat heart failure and to improve survival after a heart attack. These uses are based on the product’s regulatory label.

Q: Is it safe to stop taking Диован suddenly?

Individuals who stop taking high blood pressure medication suddenly may experience an increase in blood pressure. Any changes to the medication regimen should be discussed and managed only under the direct supervision of a healthcare professional.

Q: What should I do if I miss a dose?

If a dose is missed, it is generally advised to take the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Do not take two doses at the same time. Specific guidance for missed doses should always come from the prescribing healthcare provider.

Q: Can I drink alcohol while taking Диован?

Combining alcohol with blood pressure medication like Диован may potentially lead to an excessive drop in blood pressure, which could cause dizziness or fainting. It is advisable to consult a healthcare professional regarding moderate alcohol consumption while on this medication.

Q: Does Диован cause weight gain?

Weight gain is not typically listed as a common side effect of valsartan in the official product information. However, medication side effects can vary among individuals. If there are concerns about unexplained weight changes, a healthcare professional should be consulted.

How to Store and Dispose of Diovan

The storage and disposal of Diovan (valsartan) and Diovan HCT (valsartan/HCTZ) must follow official guidelines to maintain stability and safety.

Storage Requirements

Product Form	Temperature & Protection	Specific Handling & In-Use Stability
Diovan HCT Tablets	Store at 25 C (77 F); excursions permitted to 15-30 C (59-86 F). Protect from moisture.	Keep the medication tightly closed and dispense in a tight container.
Prepared Oral Suspension	Store below 30 C (86 F) for up to 30 days, or refrigerated (2 C to 8 C) for up to 75 days.	Shake the bottle well for at least 10 seconds before dispensing. Discard after the stated stability period.

All forms must be kept out of the reach of children.

Disposal

To dispose of unused or expired Diovan, utilize a drug take-back program when available. If a program is not accessible, mix the medication with an undesirable substance (e.g., dirt, coffee grounds) in a sealed bag or container, and discard in the household trash. Do not flush this medication unless explicitly instructed.